 |
24 Diseases |  |
0 Trials |
|
0 Trials |  |
32 News |  |
- || cendakimab (CC-93538) / AbbVie, BMS, dectrekumab (QAX576) / Novartis, Dupixent (dupilumab) / Sanofi, Regeneron
Retrospective data, Review, Journal: Efficacy and Safety of Monoclonal Antibodies for the Treatment of Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - May 6, 2024
MAbs seem effective and safe in reducing esophageal eosinophil infiltrate, EoE-HSS score, EREFS score, and dysphagia symptoms in patients with EoE. However, further evidence is needed to establish its place in EoE management.
- || Review, Journal: The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs. (Pubmed Central) - Feb 10, 2024
Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets.
- | budesonide / Generic mfg.
Journal: Current options and investigational drugs for the treatment of eosinophilic esophagitis. (Pubmed Central) - Feb 26, 2022
These include monoclonal antibodies (including mepolizumab, reslizumab, benralizumab, dectrekumab, cendakimab, and dupilumab), JAK-STAT blockers, and S1PR agonists, among others...Therapies under investigation potentially can target multiple Th2-associated diseases that converge in EoE patients. Therapeutic strategies require a personalized and patient-centered approach to reduce the burden of the disease, and cost-effectiveness analysis to position their use in a complex therapeutic landscape.
- | Jorveza (budesonide orodispersible tablets) / Dr Falk
Retrospective data, Journal: A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children. (Pubmed Central) - Jul 10, 2021
This meta-analysis showed that budesonide 1 mg orodispersible tablet twice daily was the best treatment for EoE, as it was the most effective. This treatment remained the optimal approach in adult patients, whereas fluticasone was the best treatment in pediatric patients.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Xolair (omalizumab) / Roche, Novartis
Journal: Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. (Pubmed Central) - Jun 30, 2021
Several additional promising therapies are also discussed.Expert opinion: Several therapeutic targets have shown efficacy and will be approved to treat EoE, especially corticosteroid-sparing options and those for patients with multiple Th2-associated diseases. Personalized therapeutic strategies for initial and maintenance treatments of EoE must be rationally designed, to reduce the burden of disease and answer meaningfully the needs of all stakeholders involved in EoE.
- ||| Eosinophilic Esophagitis Drug Markets, 2028 - Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan - https://t.co/guyiBzPH8C https://t.co/S8GRJErfKm (Twitter) - Apr 19, 2021
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Xolair (omalizumab) / Roche, Novartis
Review, Journal: Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review. (Pubmed Central) - Jan 30, 2020
Additionally, anti-allergic targets, immunosuppressives, and monoclonal antibodies (such as mepolizumab, reslizumab, QAX576, RPC4046, dupilumab, omalizumab, and infliximab) that have been evaluated as treatments for EoE are summarized. Finally, several promising therapeutic agents (e.g., sialic acid-binding immunoglobulin-like lectin 8 antibodies, the transforming growth factor-β1 signal blocker losartan, CC chemokine receptor type 3 antagonists, thymic stromal lymphopoietin antibodies, antibodies targeting the α4β7 integrin, anti-interleukin-9 antibodies, and anti-interleukin-15 antibodies) that target specific molecules or cells implicated in the pathogenesis of EoE are proposed.
- || QBX-258 / Novartis, dectrekumab (QAX576) / Novartis
Trial completion: Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL) (clinicaltrials.gov) - May 30, 2018
P=N/A, N=9, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Finally, several promising therapeutic agents (e.g., sialic acid-binding immunoglobulin-like lectin 8 antibodies, the transforming growth factor-β1 signal blocker losartan, CC chemokine receptor type 3 antagonists, thymic stromal lymphopoietin antibodies, antibodies targeting the α4β7 integrin, anti-interleukin-9 antibodies, and anti-interleukin-15 antibodies) that target specific molecules or cells implicated in the pathogenesis of EoE are proposed. Active, not recruiting --> Completed
- QBX-258 / Novartis, dectrekumab (QAX576) / Novartis
Trial primary completion date: Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL) (clinicaltrials.gov) - May 25, 2017
P=N/A, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Jul 2018
- QBX-258 / Novartis, dectrekumab (QAX576) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date: Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL) (clinicaltrials.gov) - May 25, 2016
P=N/A, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jul 2017 --> Jul 2018 Recruiting --> Active, not recruiting | N=22 --> 9 | Trial primary completion date: Jul 2016 --> Jul 2017
- dectrekumab (QAX576) / Novartis
Enrollment change, IO biomarker: Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma (clinicaltrials.gov) - Mar 5, 2016
P1/2, N=0, Withdrawn, Sponsor: Novartis
Recruiting --> Active, not recruiting | N=22 --> 9 | Trial primary completion date: Jul 2016 --> Jul 2017 N=60 --> 0
- |||| QBX-258 / Novartis, dectrekumab (QAX576) / Novartis, VAK694 / Novartis
Trial completion: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Jan 12, 2016
P2, N=65, Completed, Sponsor: Novartis Pharmaceuticals
N=60 --> 0 Recruiting --> Completed
- QBX-258 / Novartis, dectrekumab (QAX576) / Novartis
New trial: Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL) (clinicaltrials.gov) - Jul 10, 2015
P=N/A, N=22, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- dectrekumab (QAX576) / Novartis
Trial completion: A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease (clinicaltrials.gov) - May 28, 2015
P2, N=3, Completed, Sponsor: Gerhard Rogler
Recruiting --> Completed Recruiting --> Completed
- || QBX-258 / Novartis, dectrekumab (QAX576) / Novartis, VAK694 / Novartis
Trial primary completion date: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Apr 28, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Nov 2014 --> Apr 2015
- || QBX-258 / Novartis, dectrekumab (QAX576) / Novartis, VAK694 / Novartis
Trial completion date: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Apr 28, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2014 --> Apr 2015 Trial completion date: Nov 2014 --> Apr 2015
- dectrekumab (QAX576) / Novartis
Enrollment change: Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Apr 1, 2014
P2, N=40, Terminated, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2014 --> Apr 2015 N=60 --> 40
- dectrekumab (QAX576) / Novartis
Enrollment change: A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients (clinicaltrials.gov) - Feb 5, 2014
P2, N=10, Completed, Sponsor: Novartis Pharmaceuticals
N=60 --> 40 N=19 --> 10
- ||| dectrekumab (QAX576) / Novartis
Enrollment change: Efficacy of QAX576 in Asthma (clinicaltrials.gov) - Aug 20, 2013
P2, N=259, Completed, Sponsor: Novartis Pharmaceuticals
N=19 --> 10 N=486 --> 259
- dectrekumab (QAX576) / Novartis
Trial termination: Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Mar 28, 2013
P2, N=40, Terminated, Sponsor: Novartis Pharmaceuticals
N=486 --> 259 Recruiting --> Terminated
- dectrekumab (QAX576) / Novartis
Trial completion: A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients (clinicaltrials.gov) - Mar 17, 2013
P2, N=10, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated Recruiting --> Completed
- ||| dectrekumab (QAX576) / Novartis
Enrollment change: SD, IL-13 Production Rate in IPF (clinicaltrials.gov) - Nov 26, 2012
P2, N=52, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=31 --> 52
- | dectrekumab (QAX576) / Novartis
Trial completion: Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis (clinicaltrials.gov) - Jun 26, 2012
P2, N=25, Completed, Sponsor: Novartis Pharmaceuticals
N=31 --> 52 Active, not recruiting --> Completed
- |||| dectrekumab (QAX576) / Novartis
Trial completion: Efficacy of QAX576 in Asthma (clinicaltrials.gov) - May 1, 2012
P2, N=259, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||| QBX-258 / Novartis, dectrekumab (QAX576) / Novartis, VAK694 / Novartis
Trial initiation date: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Apr 24, 2012
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Nov 2011 --> Feb 2012
- |||| QBX-258 / Novartis, dectrekumab (QAX576) / Novartis, VAK694 / Novartis
Enrollment open: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Apr 24, 2012
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Nov 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- | QBX-258 / Novartis, dectrekumab (QAX576) / Novartis
New P1 trial: To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma (clinicaltrials.gov) - Mar 28, 2012
P1, N=50, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| QBX-258 / Novartis, dectrekumab (QAX576) / Novartis, VAK694 / Novartis
New P2 trial: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (clinicaltrials.gov) - Nov 22, 2011
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals